This study was to investigate the efficacy and safety of regorafenib or fruquintinib combined with camrelizumab in patients with microsatellite stable (MSS) and/or proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC). Medical records of MSS/pMMR mCRC patients who received regorafenib (80 mg) or fruquintinib (3 mg) once a day (21 days on/7 days off) plus camrelizumab (200 mg) every three weeks in Yuhuangding Hospital between January 2020 and June 2020 were retrospectively collected. Follow-up data up to November 1st, 2020 was gathered. The primary endpoint was the objective response rate (ORR) and disease control rate (DCR). The safety profile was the secondary endpoint. A total of 16 patients were enrolled. The ORR was 25.0% (4/16) and the DCR was 62.5% (10/16). The main adverse events (AEs) included reactive cutaneous capillary endothelial proliferation (RCCEP) (81.3%), fatigue (43.8%), hypertension (37.5%), hand-foot skin reaction (25.0%), and thyroid dysfunction (25.0%). Most AEs were grade 1 or 2, with only 1 patient of grade 3 liver dysfunction. All the AEs were ameliorated by effective symptomatic treatment. Regorafenib or fruquintinib plus camrelizumab exhibited promising efficacy in patients with MSS/pMMR mCRC. The toxicity was moderate and manageable.

中文翻译：

---

瑞戈非尼或呋喹替尼加卡瑞利珠单抗在微卫星稳定和/或精通错配修复转移性结直肠癌患者中的疗效和安全性：一项观察性初步研究。

本研究旨在探讨瑞格非尼或呋喹替尼联合卡瑞利珠单抗治疗微卫星稳定型 (MSS) 和/或高效错配修复 (pMMR) 转移性结直肠癌 (mCRC) 患者的疗效和安全性。2020年1月至6月在玉皇顶医院接受瑞戈非尼（80mg）或呋喹替尼（3mg）每日一次（21天/7天）加卡瑞利珠单抗（200mg）每三周一次的MSS/pMMR mCRC患者病历2020年是回顾性收集的。收集了截至 2020 年 11 月 1 日的后续数据。主要终点是客观缓解率（ORR）和疾病控制率（DCR）。安全概况是次要终点。共有 16 名患者入组。ORR 为 25.0% (4/16)，DCR 为 62.5% (10/16)。主要不良事件（AEs）包括反应性皮肤毛细血管内皮增生（RCCEP）（81.3%）、疲劳（43.8%）、高血压（37.5%）、手足皮肤反应（25.0%）和甲状腺功能障碍（25.0%） . 大多数 AE 为 1 级或 2 级，仅有 1 名患者出现 3 级肝功能不全。通过有效的对症治疗，所有不良事件均得到改善。瑞戈非尼或呋喹替尼加卡瑞利珠单抗在 MSS/pMMR 转移性结直肠癌患者中表现出良好的疗效。毒性适中且可控。瑞戈非尼或呋喹替尼加卡瑞利珠单抗在 MSS/pMMR 转移性结直肠癌患者中表现出良好的疗效。毒性适中且可控。瑞戈非尼或呋喹替尼加卡瑞利珠单抗在 MSS/pMMR 转移性结直肠癌患者中表现出良好的疗效。毒性适中且可控。